Evidence map›Paper›PMID 17016440›Full record

ArticleOncogene2007

STAT1-independent inhibition of cyclooxygenase-2 expression by IFNgamma; a common pathway of IFNgamma-mediated gene repression but not gene activation.

L Klampfer, J Huang, P Kaler, T Sasazuki, S Shirasawa, L Augenlicht

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease.Immunology and allergy clinics of North America · 2016
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes.Proceedings of the National Academy of Sciences of the United States of America · 2009
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

L KlampferDepartment of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY 10467, USA. lklampf@aecom.yu.edu
J Huang
P Kaler
T Sasazuki
S Shirasawa
L Augenlicht
Albert Einstein College of Medicine · USSaitama International Medical Center · JPMontefiore Medical Center · US

Funding

MOLECULAR-NUTRIENT INTERACTIONS IN INTESTINAL CANCERU54CA100926 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI AUGENLICHT, LEONARD H · 2003 to 2008
$9.7M
Oncogenic Ras, STAT1 and ChemopreventionR01CA111361 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI KLAMPFER, LIDIJA · 2005 to 2009
$1.1M
NCI NIH HHS R01 CA111361NCI NIH HHS U54 CA100926PHS HHS P30-13330
6 · The paper itself

Abstract

Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in the synthesis of prostaglandins, promotes the development of colorectal cancer, and is a key molecular target of non-steroidal anti-inflammatory drugs, compounds that reduce the relative risk of developing colon cancer. In this study, we showed that interferon gamma (IFNgamma) inhibits the expression of COX-2 protein in intestinal epithelial cells (IECs) through a pathway that requires Janus-activated kinase (JAK) activity. In contrast, we demonstrated that transcriptional inhibition of COX-2 by IFNbeta or IFNgamma occurs in cells with silenced signal transducer and activator of transcription 1 (STAT1) expression and that IFNs retained the ability to inhibit COX-2 transcription in cells with activated RasV12, in which IFNgamma failed to induce STAT1. Thus, unlike the activity of JAK, STAT1 is not required for the inhibition of COX-2 expression by IFNgamma. In contrast to COX-2, the activation of genes in response to IFNgamma, such as interferon regulatory factor-1, was severely impaired by both STAT1 silencing and by constitutive Ras signaling. To determine whether there is a general differential requirement for STAT1 in gene activation and gene repression in response to IFNgamma in intestinal cells, we performed genome-wide analysis of IFNgamma target genes in an IEC line in which STAT1 expression was silenced by small interfering RNA. The results confirmed that the activation of the majority of genes by IFNgamma required STAT1. In contrast, the repression of several genes, as we showed for COX-2 specifically, was largely unaffected in cells with silenced STAT1. Our results therefore demonstrate that in general gene activation by IFNgamma is more sensitive to STAT1 deficiency than gene repression, and suggest that IFNgamma activates and represses gene expression via distinct pathways that can be distinguished, at least in part, by their requirement for STAT1.

Indexed as

Down-RegulationCells, CulturedCyclooxygenase 2Gene ExpressionGene SilencingHumansInterferon-gammaIntestinal MucosaJanus KinasesOligonucleotide Array Sequence AnalysisProtein BiosynthesisRNA, Small InterferingSTAT1 Transcription FactorTranscriptional ActivationCyclooxygenase 2Interferon-gammaJanus KinasesRNA, Small InterferingSTAT1 Transcription Factor

Identifiers

PMID17016440
OpenAlexW2164081856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.